Physician profile
Noelle Decell
NPI 1609572791
$2,192.68
in general payments reported to CMS, 2019-2025
33 companies · $833 in 2025
The $833 reported for 2025 was more than what 80% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $455 · 2024: $905 · 2025: $833.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,193.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,192.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $523.59 | 2023-2025 | |
| Novo Nordisk INC | $319.68 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $163.92 | 2023-2025 | Jardiance, Ofev |
| Dexcom, INC. | $151.29 | 2024-2025 | Dexcom G6 Transmitter |
| Lilly USA, LLC | $132.19 | 2023-2025 | Jardiance, Mounjaro, Emgality |
| Glaxosmithkline, LLC. | $102.98 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Azurity Pharmaceuticals, INC. | $86.61 | 2023-2025 | Horizant, Azmiro, Horizant |
| Axsome Therapeutics, INC. | $63.95 | 2024-2025 | Auvelity |
| Amgen INC. | $59.46 | 2025 | Repatha, Otezla |
| Astellas Pharma US INC | $52.35 | 2025 | Veozah |
| Pfizer INC. | $51.51 | 2024-2025 | |
| Depuy Synthes Sales INC. | $37.82 | 2025 | Motoband |
| Exact Sciences Corporation | $37.79 | 2024 | Cologuard Collection Kit |
| Astrazeneca Pharmaceuticals LP | $36.33 | 2024-2025 | Airsupra, Farxiga |
| Inspire Medical Systems, INC. | $33.38 | 2024 | Inspire |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $30.75 | 2024 | |
| Si-Bone, INC. | $25.92 | 2025 | |
| Inari Medical, INC. | $25.56 | 2023 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $24.35 | 2025 | Xifaxan |
| Dynavax Technologies Corporation | $21.35 | 2023 | Heplisav-B |
| Avvisto Therapeutics, LLC | $20.21 | 2025 | Cycloset |
| Amarin Pharma, INC. | $20.16 | 2023 | |
| Ultragenyx Pharmaceutical INC. | $17.35 | 2024 | Crysvita |
| Siemens Medical Solutions USA, INC. | $17.31 | 2024 | Magnetom Skyra |
| Renalytix Ai, INC. | $16.90 | 2025 | Kidneyintelx Blood Collection Convenience Kit |
| Nevro Corp. | $16.25 | 2024 | Senza |
| Tolmar, INC. | $15.95 | 2025 | Jatenzo |
| Kowa Pharmaceuticals America, INC. | $15.46 | 2025 | Zoryve |
| Acella Pharmaceuticals, LLC | $15.45 | 2025 | NP Thyroid 60 |
| Esperion Therapeutics, INC. | $14.87 | 2024 | Nexletol |
| Bayer Healthcare Pharmaceuticals INC. | $14.55 | 2025 | |
| Merck Sharp & Dohme LLC | $14.15 | 2024 | Gardasil, Capvaxive, Gardasil 9 |
| Phathom Pharmaceuticals, INC. | $13.29 | 2024 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Noelle Decell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.